BioSpace News Archive

Ambys Medicines, a company aiming to be the leader in cell therapy for severe liver disease by unlocking the full potential of hepatocyte transplantation, today announced the appointment of Markus Grompe, M.D., as the company’s Chief Scientific Officer.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced that seven abstracts were selected for presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Mr. Ko’s presentation will be available on demand beginning on December 6, 2021 at 7:00 a.m. ET. Please visit here to learn more about the event and to register.

Emergen Research has published its latest report titled “Culture Media Market, By Type, By Research Type, By Application, By End-use, and By Region Forecast to 2028”

According to Emergen Research, the global Fc fusion protein market size was USD 26.97 billion in 2020 and is expected to reach USD 59.48 billion in 2028 and register a revenue CAGR of 10.5% during the forecast period, 2021-2028.

According to Emergen Research, the global targeted therapeutics market size was USD 93.75 Billion in 2020 and is expected to reach USD 162.89 Billion in 2028 and register a revenue CAGR of 7.1% during the forecast period, 2021-2028.

According to Emergen Research, the global wireless brain sensor market size was USD 391.7 million in 2020 and is expected to reach USD 804.3 million in 2028 and register a revenue CAGR of 9.5% during the forecast period, 2021-2028.

Sino Biological’s new Omicron product line includes recombinant Omicron Spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognizing the Omicron Spike protein, and the Omicron pseudovirus assay CRO service.

Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in Frontiers in Oncology, section Gastrointestinal Cancers: Gastric & Esophageal Cancers.

Bsense Bio Therapeutics Ltd., a FutuRx portfolio biopharmaceutical company dedicated to developing novel therapeutics for treatment of sensory hyperexcitability disorders, today announced positive topline data in a comparative preclinical study of its leading compound BSEN627 with pregabalin in chronic pain.